The study of clinical effectiveness and safety of a combination of 0.4% minoxidil and 0.05% retinaldehyde nanoparticles solution for treatment of androgenetic alopecia

Phase 2

Recruiting

• Conditions: Androgenetic alopecia; Androgenetic Alopecia; Female pattern hair loss; Topical nanominoxidil; Topical retinaldehyde nanoparticles

• Registration Number: TCTR20201104003
• Lead Sponsor: ermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-11-04
• Study Completion: 2021-05-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1.Patient with androgenetic alopecia with Norwood-Hamilton grade 3-4 or Ludwig
2.Volunteers who have well adherence and can be followed up as appointed grade 1-2

Exclusion Criteria

1.Prior treatment of androgenetic alopecia with topical therapy within 3 months
2.Prior treatment of androgenetic alopecia with oral therapy within 6 months
3.Prior treatment of androgenetic alopecia with hair transplantation within 12 months
4.Pregnancy or breastfeeding
5.Hirsutism
6.Abnormal thyroid function
7.Iron deficiency anemia
8.Patient recieved contraception or hormone replacement therapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
number of hair week 0,12,24 hair count with tricoscale

Secondary Outcome Measures

Name	Time	Method
Quality of life Week 0,12,24 Questionnaire,Side effect Week 0,12,24 Questionnaire